Biotech | February 23, 2022
Merck completes acquisition of biopharma CDMO Exelead
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
According to the state government, it will also provide support to special projects such as preclinical testing, genome sequencing in the private sector, private sector BSL-3 lab-vaccine development and manufacturing and testing and certification laboratories
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Newly formed Life Science Services business unit to offer fully integrated CDMO and Contract Testing Services
It will enable the company to branch out to new geographies and strengthen its presence in South Africa
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
Subscribe To Our Newsletter & Stay Updated
